Back HIV/AIDS

HIV / AIDS

IAS 2015: Long-term HIV Remission [VIDEO]

A French teenager with HIV who has maintained an undetectable viral load for 12 years while off antiretroviral treatment was among the most widely discussed topics at the 8th International AIDS Society Conference last week in Vancouver. While no one is calling this case a cure, it does raise interesting questions about "post-treatment control" and may provide clues about how to achieve a functional cure or long-term HIV remission.

alt

IAS 2015: The Health Economics of HIV Treatment [VIDEO]

The world faces an opportunity to expand antiretroviral therapy to all who need it -- both to improve the health of individuals living with HIV and to prevent transmission of the virus -- and treatment would likely be cost-effective, experts agreed at a press briefing at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention last week in Vancouver.

alt

IAS 2015: Test and Treat Studies and African Country Experience Show 90-90-90 Targets Are Achievable

Health services in some African countries including Botswana, Rwanda, and Malawi are now providing effective HIV treatment to a greater proportion of their HIV-positive citizens than the U.S. and other rich countries. Meanwhile, some of the first data to come from large African studies examining the population-level impact of treatment as prevention suggest that the objectives of testing and treating 90% of those eligible can be achieved.

alt

IAS 2015: U.S. PrEP Demo Project Finds People at Highest HIV Risk Take PrEP Most Consistently

An open-label demonstration project of Truvada pre-exposure prophylaxis (PrEP) in the U.S. has found generally high retention and adherence rates, with the highest adherence among people at the highest risk of HIV infection, researchers reported at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) last week in Vancouver. However, some groups appeared to have more difficulty taking PrEP -- most notably young people and black people, and it proved difficult to recruit black men and transgender women -- to the project.

alt

IAS 2015: Switching to Tenofovir Alafenamide Keeps HIV Suppressed, Helps Kidneys and Bones

People who switch from the current version of tenofovir (TDF) to tenofovir alafenamide (TAF) -- a new formulation that reaches higher levels in HIV-infected cells -- maintained undetectable viral load and saw improvements in kidney function biomarkers and bone density, according to a pair of studies presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last week in Vancouver.

alt

IAS 2015: Treatment Cascades Show 90-90-90 Goals Reachable, Eastern Europe Lags Behind Africa

A global analysis of HIV treatment cascades -- the proportions of people diagnosed with HIV, in care, on treatment, and virally suppressed -- shows that some of the world’s richest countries still fall far short of achieving the UNAIDS 90-90-90 targets, research from Imperial College London shows. Progress is worst in Eastern Europe, where most countries lag behind average performance in sub-Saharan Africa on every indicator.

alt

 

IAS 2015: Raltegravir Prevents Mother-to-Child HIV Transmission During Late Pregnancy

Combination antiretroviral therapy containing the integrase inhibitor raltegravir (Isentress) appears safe and effective and may be an attractive option for treatment of pregnant women with HIV -- and potentially their infants -- to prevent perinatal transmission, according to study findings presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last week in Vancouver.

alt